FOLH1 and prostate carcinoma: In the experiments of Shanta Dhar et al. [43], the hydrophobic Pt (IV) compound 1 was used as a prodrug for delivering cisplatin to prostate cancer by PSMA-targeted PLGA-b-PEG-NPs, which were made of poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG) nanoparticles (NPs).